Korean J Physiol Pharmacol.
2000 Dec;4(6):507-513.
Role of Shc and phosphoinositide 3-kinase in heregulin-induced
mitogenic signaling via ErbB3
- Affiliations
-
- 1Department of Pharmacology, College of Dentistry, Chosun University,
Kwang-Ju, South Korea. msakim@mail.chosun.ac.kr
Abstract
- ErbB3/HER3 is a cell surface receptor which belongs to the ErbB/HER
subfamily of receptor protein tyrosine kinases. When expressed in
NIH/3T3 cells, ErbB3 can form heterodimeric coreceptor with endogenous
ErbB2. Among known intracellular effectors of the ErbB2/ErbB3 are
mitogen-activated protein kinase (MAPK) and phosphoinositide (PI)
3-kinase. In the present study, we studied relative contributions of
above two distinct signaling pathways to the heregulin-induced
mitogenic response via activated ErbB3. For this, clonal NIH-3T3 cell
lines expressing wild-type ErbB3 and ErbB3 mutants were stimulated with
heregulin beta1. While cyclin D1 level was markedly high and further
increased by treatment of heregulin in cells expressing wild-type
ErbB3, the elimination of either Shc binding or PI 3-kinase binding
lowered both levels. This result was supported by the reduction of
cyclin D1 expression by preteatment with MAPK kinase inhibitor or PI
3-kinase inhibitor before stimulation with heregulin. In accordance
with the cyclin D1 expression, elimination of either Shc binding or PI
3-kinase binding reduced the heregulin-induced DNA synthesis and cell
growth rate. Our results obtained by the comparison of wild-type and
ErbB3 mutants indicate that the full induction of the cell cycle
progression through G1/S phase by ErbB3 activation is dependent on both
Shc/MAPK and PI 3-kinase signal transduction pathways.